As of November 6, 2026, Edgewise Therapeutics, Inc. is a publicly traded company (Nasdaq: EWTX); its largest reported holder is Paradigm BioCapital Advisors LP, with 9.5% on Schedule 13G/A of August 14, 2026, then RA Capital (7.8%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Edgewise Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Edgewise Therapeutics, Inc. a real, registered company?
- Edgewise Therapeutics, Inc. files with the SEC under CIK 1710072 (its SEC filings).
- Its shares are listed under the ticker EWTX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boulder, Colorado, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under EDGEWISE THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Paradigm BioCapital Advisors LP (filed 2026-08-14).
Who are Edgewise Therapeutics, Inc.'s owners and officers?
Edgewise Therapeutics, Inc.: incorporated in Delaware; business address in Boulder, Colorado; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 0.9% |
| Schedule 13G/A, 2026-08-14 | Paradigm Biocapital Advisors LP | 9.5% |
| Schedule 13G/A, 2026-08-14 | Baker Bros. Advisors LP | 3.4% |
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 7.8% |
| Schedule 13G, 2026-08-06 | Fmr LLC | 5.1% |
| Schedule 13G, 2026-05-15 | Janus Henderson Group PLC | 5.5% |
| Schedule 13D/A, 2026-04-27 | Novo Holdings A/S | 4.9% |
| Schedule 13G/A, 2026-02-17 | Paradigm Biocapital Advisors LP | 6.2% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 4.7% |
| Schedule 13G/A, 2025-11-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2025-08-14 | Janus Henderson Group PLC | 5.2% |
| Schedule 13G/A, 2025-08-14 | Perceptive Advisors LLC | 4.4% |
Questions about who owns Edgewise Therapeutics, Inc.
Who owns Edgewise Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Edgewise Therapeutics, Inc.: Paradigm Biocapital Advisors LP (9.5%, Schedule 13G/A, filed 2026-08-14), Ra Capital Management, L.P. (7.8%, Schedule 13G/A, filed 2026-08-14) and Janus Henderson Group PLC (5.5%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Edgewise Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Edgewise Therapeutics, Inc. on this page are Paradigm Biocapital Advisors LP (9.5%), Ra Capital Management, L.P. (7.8%) and Janus Henderson Group PLC (5.5%).
When did Paradigm Biocapital Advisors LP buy into Edgewise Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Paradigm Biocapital Advisors LP on this page is the Schedule 13G/A, filed 2026-02-17, reporting 6.2%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Edgewise Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Edgewise Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Edgewise Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Edgewise Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- OrbiMed, a director and 10% owner: 443,792 shares (0.41% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-04-04).
- , a director and 10% owner: 443,792 shares (0.41% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2025-04-04).
- OrbiMed Genesis GP LLC, a director and 10% owner: 443,792 shares (0.41% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-04-04).
- OrbiMed Capital GP VI LLC, a director and 10% owner: 443,792 shares (0.41% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-04-04).
- , the chief financial officer: 86,162 shares (0.08% of shares outstanding) (Form 4, 2025-08-14).
Shares outstanding: 109,482,763 as of 2026-10-31, from the company's latest SEC cover page.
How much has Edgewise Therapeutics, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-07-13).
Keep reading
More on Edgewise Therapeutics, Inc. and the records around it.
Edgewise Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/edgewise-therapeutics